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CIA = collagen-induced arthritis; CII = collagen type II; G6PI = glucose-6-phosphate isomerase; IL = interleukin; MHC = major histocompatibility
complex; RA = rheumatoid arthritis; TCR = T-cell receptor; Th = T helper; TNF = tumour necrosis factor.
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Introduction
The aetiology of rheumatoid arthritis (RA), which affects
approximately 1% of the population, remains obscure.
There is considerable evidence suggesting that RA is an
autoimmune disease in which autoreactive lymphocytes
trigger macrophages, synoviocytes and other effector cells
that mediate synovitis and the destruction of cartilage and
bone [1–7].
B and T lymphocytes in rheumatoid arthritis
and experimental models
Approximately two-thirds of RA patients produce
rheumatoid factors – autoantibodies that are directed
against IgG [8]. Because of this strong and diagnostically
relevant association, B lymphocytes were long suspected
to be the main culprits in RA pathogenesis [1,8]. RA
susceptibility and severity are strongly associated with
certain HLA-DR haplotypes in Caucasians [9]. The
discovery of this linkage led to a more T-cell centred view
[3,9–13] because antigen presentation to T lymphocytes
is the only known immunological function of MHC class II
molecules such as HLA-DR. The difficulty in detecting
cellular immune responses against autoantigens in RA
patients [14–16], together with the failure of some T-cell
directed immunomodulatory treatment strategies [17–22]
and impressive successes of therapeutic tumour necrosis
factor (TNF)-α blockade in RA, appeared to implicate
macrophages as the major effector cells in the clinically
overt stages of RA [7,23].
Most recently, however, two different lines of evidence re-
assert the importance of T cells. First, a large clinical trial
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Abstract
The antigens that trigger the pathogenic immune response in rheumatoid arthritis (RA) remain
unknown. Until recently it was assumed that either viral or microbial antigens, or joint-specific
antigens were the target of arthritogenic T and B lymphocytes in RA. Consequently, murine models of
arthritis are induced by immunization with either joint-specific antigens such as type II collagen or
microbial products such as streptococcal cell wall. In the K/B×N T-cell receptor transgenic mouse
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shown that G6PI immunization induces severe symmetrical peripheral polyarthritis in genetically
unaltered DBA/I mice. In that model CD4+ T cells are necessary not only for the induction but also for
the effector phase of arthritis. Here we review the pathomechanisms that lead from systemic
autoreactivity to arthritis in these models, consider the relevance of anti-G6PI immune reactivity for
RA, and discuss the insights into the pathogenesis of RA and possibly other autoimmune conditions
that can be gained from these models.
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[24] showed clear clinical benefits from treating active RA
by blocking T-cell costimulation and activation. Second, a
spontaneous point mutation in the gene encoding an Src
homology 2 (SH2) domain of ZAP-70, a key signal
transduction molecule in T cells, causes chronic auto-
immune arthritis in mice that resembles human RA in many
respects [25]. Moreover, the pathogenic importance of B
lymphocytes is again becoming appreciated [26,27],
partly because depletion of these cells has been shown to
be a successful treatment for RA patients [28]. Taken
together, a consensus is beginning to emerge that many
different cell types, both from the innate and the adaptive
immune systems, are crucial to the pathogenesis of RA [4].
Arthritogenic cartilage antigens?
Although some autoantibodies, such as rheumatoid
factors that recognize IgG and antibodies against
citrullinated antigens, have diagnostic significance
[8,29,30], the autoantigen(s) that are recognized in
chronic inflammatory arthritides such as RA are unknown
[5,16,22,31,32]. Collagen type II (CII) is the major protein
in articular cartilage. It is a candidate autoantigen for RA
because antibodies and perhaps T cells against CII occur
in patients with RA [5,33–35] and because it is
arthritogenic in animals [36]. Collagen-induced arthritis
(CIA) has thus become the most intensively studied
murine model for human inflammatory arthritides [37].
Autoantibodies are important players in CIA. Adoptive
transfer of either polyclonal IgG antibodies purified from
the sera of arthritic mice [38–40] or combinations of
monoclonal antibodies against CII [41] can induce arthritis
even in mouse strains that are not susceptible to actively
induced CIA [38]. This form of adoptively transferred
arthritis has been called CII antibody-induced arthritis
[42]. Antibodies against CII are also found in the blood
and joints of some RA patients [33,34,43,44]. In contrast,
the role of T lymphocytes in the pathogenesis of CIA is
less clear. Collagen-specific proinflammatory T cells can
be demonstrated in the blood and synovial fluid of mice
with CIA [45]. However, most attempts to induce CIA in
mice by T-cell transfer have been unsuccessful [46] and
CD4-deficient mice develop CIA with unaltered incidence
and severity [47]. Mice lacking α/β T cells are resistant to
CIA, whereas γ/δ T cells are neither necessary nor
protective. A single report on CIA, albeit at reduced
severity as compared with wild-type littermates, in rag-
deficient DBA/1 mice [48] has not been corroborated by
others to date. Taken together, the question regarding
how T cells operate in the pathogenesis of CIA has not yet
been answered definitively.
CII-specific T cells have also been difficult to demonstrate
in the blood or synovial fluid of RA patients [15,49–51].
Moreover, attempts to treat RA by inducing T-cell
tolerance to CII have yielded disappointing results
[18,19,22,52]. Taken together, there is little solid
evidence that CII or any other single joint-specific antigen
such as collagen type XI [53], gp39 [54], cartilage
oligomeric matrix protein [55], or cartilage proteoglycan
(aggrecan) [56] is a diagnostically or pathogenetically
significant autoantigen in all RA patients. Given the
complexity and clinical and pathological diversity of RA, it
seems more likely that different autoantigens are important
in different subsets of RA patients.
Arthritogenic noncartilagenous antigens?
Some noncartilagenous antigens have been used to induce
and study arthritis in mice and rats [37]. These are either
various microbial compounds with adjuvant effects and/or
antigenic properties as in adjuvant arthritis, CpG induced
arthritis, or streptococcal cell wall induced arthritis [57–61];
or antigens directly injected into the joints of experimental
animals following systemic immunization (antigen-induced
arthritis) [62,63]. These arthritides are not the subject of this
review because the inciting noncartilagenous antigens are
non-self antigens. The importance of noncartilagenous self-
antigens to the pathophysiology of arthritis had not been
considered until recently.
Autoreactivity against a systemically expressed
antigen causes symmetrical peripheral
polyarthritis in TCR transgenic K/B×N mice
A T-cell receptor (TCR)-transgenic mouse model of
arthritis has challenged the concept that arthritis
necessarily results from an autoimmune attack against
joint-specific antigens. When C57BL/6 mice expressing a
transgene-encoded TCR recognizing amino acids 41–61
of bovine ribonuclease bound to the MHC molecule I-Ak
(the ‘KRN’ receptor) were inadvertently crossed with
diabetes-susceptible NOD mice, all of the F1 offspring
(the K/B×N mice) spontaneously developed peripheral
symmetrical polyarthritis [64]. Arthritis in the K/B×N mice
resembles RA in that it symmetrically affects the small
peripheral joints. In contrast to RA, the distal
interphalangeal joints are regularly affected in K/B×N
mice, there are no systemic manifestations, the mice do
not produce rheumatoid factors, and the arthritis does not
remit [64]. Thus, K/B×N mice spontaneously develop
peripheral polyarthritis that resembles human RA in many
clinical and pathological respects. This surprising finding
induced intense research into the pathophysiology of
arthritis in the K/B×N mice.
KRN T cells and I-Aβ βg7 molecules are
necessary for the induction but not the
effector phase of arthritis in K/B×N mice
Both the KRN TCR and one copy of the NOD I-Aβg7 MHC
molecule are necessary for development of arthritis in
K/B×N mice. Neither KRN TCR transgenic C57BL/6 mice
nor the F1 from crosses of the transgene-expressing
C57BL/6 mice with strains other than the I-Aβg7-bearing22
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NOD mice develop arthritis. KRN T cells proliferate in
response to I-Aβg7APC in the absence of experimentally
added antigens [65]. Importantly, Th cells are only
necessary in the induction phase of arthritis. Once the
pathogenesis has passed a certain point, Th cells are
dispensable. Treatment with anti-CD4 antibodies is
ineffective if it is started less than 5 days before the onset
of arthritis. What, then, are the effector mechanisms that
induce arthritis in K/B×N mice? Using adoptive transfer
experiments and a variety of knockout mice, Mathis and
colleagues [65] demonstrated that immunoglobulin is
responsible for arthritis induction in K/B×N mice. Transfer
of serum (as little as 100 µl) or IgG antibodies from
arthritic K/B×N mice induced arthritis in recipient mice of
different strains, even in rag-2–/– mice that lack T and B
lymphocytes [65]. What do these autoantibodies recognize?
The pathogenic autoantibodies recognize a
ubiquitously expressed glycolytic enzyme
Quite surprisingly, the target antigen recognized by both
the transgenic T cells and the pathogenic autoantibodies
was not joint-specific but the ubiquitously expressed
glycolytic enzyme glucose-6-phosphate isomerase (G6PI,
or GPI) [66]. G6PI, also known as phosphohexose
isomerase, catalyzes the interconversion of fructose-6-
phosphate and glucose-6-phosphate [67]. It is an
essential glycolytic enzyme, expressed by all cells, and
G6PI deficiency is lethal at the two-cell stage [68].
Arthritis can be induced in recipient mice by transfer of
polyclonal IgG1 or combinations of at least two different
monoclonal IgG1 antibodies against G6PI [69]. Mice that
lack the activating FcγRIII are less susceptible to arthritis
induced by transfer of K/B×N serum than are normal mice,
pointing to FcγRIII+ effector cells in arthritis pathogenesis
[70,71]. K/B×N serum transfer arthritis in mice that lack
the inhibitory FcγRII has been reported to be similar
[70,71] or more severe than in wild-type littermates [72].
Complement, neutrophils and mast cells are
all indispensable for arthritis development
In the K/B×N transfer arthritis IgG1 antibodies against
G6PI induce several different effector functions of the
innate immune system; the alternative pathway of the
complement cascade is triggered, resulting in chemotactic
activity (but not the membrane attack complex) [70,71].
Neutrophils [73] and mast cells [74] are both required as
effector cells to mediate joint destruction.
IL-1 is important but neither TNF-α α or IL-6 is
needed for arthritis development in K/B×N
mice
In contrast to RA in humans and most other murine
models of arthritis, neither TNF-α or IL-6 is needed for
arthritis development in K/B×N mice [75,76]. TNF-α is an
important mediator of joint destruction in RA and several
murine models of it [7]. Therefore, the K/B×N model
yielded another surprising finding when it turned out that
TNF-α blockade had no effect on the development and
progression of arthritis [75]. Moreover, K/B×N serum
induced arthritis in mice that were deficient for both TNF
receptor-1 and TNF receptor-2, or lymphotoxin-α with the
same incidence and severity as in normal littermates [76].
In that same study a somewhat reduced incidence of
arthritis was noted upon serum transfer in TNF-α-deficient
mice obtained from one particular colony as compared
with wild-type controls. However, that difference was not
found with TNF-α-deficient mice obtained from a different
colony [76]. Similarly, and again in contrast to previous
findings in other murine models of arthritis [77], IL-6
deficiency had no influence on the development of K/B×N
serum transfer arthritis [76].
Taken together, the above findings indicate that
recognition of a ubiquitously expressed self-antigen by
T cells that bear a transgenically encoded receptor and
escape negative selection in the thymus [78] induces an
arthritogenic autoantibody response, which then triggers
innate immune effector mechanisms to induce arthritis.
Autoreactivity against G6PI in the
pathogenesis of RA?
This perplexing and informative model raises the question
of whether autoreactivity against G6PI is relevant to the
pathogenesis of human RA or other chronic inflammatory
arthritides. One initial report [79] indicated that IgG
antibodies against G6PI were detectable at low dilution
(1:50) in the serum of 64% of RA patients but not in
control individuals.
However, a number of other investigators did not find
increased levels of α-G6PI antibodies in the serum of
patients with RA [80–83], collagen tissue disease [81–83],
or other chronic arthritides [81,83,84]. Moreover, the
commercial G6PI preparation used in the initial study was
found to be contaminated with other proteins, and RA
sera contained antibodies against some of these other
proteins [81]. Taken together, these findings indicate that
antibodies against G6PI are not diagnostic markers for
RA. An interesting further twist in the story was added by
a recent report. van Gaalen and coworkers [85] found that
whereas only one of 55 RA patients who did not have
systemic manifestations of the disease produced
antibodies against G6PI, seven of 22 patients with
systemic manifestations (nodules or vasculitis) and 12 of
13 patients with Felty’s syndrome had detectable α-G6PI
antibodies in their sera [85]. Thus, the possibility remains
that antibodies against G6PI occur frequently in Felty’s
syndrome. However, it is currently not yet clear whether
the increased seropositivity is specific for antibodies
against G6PI or a sign of generally dysregulated auto-
antibody production in patients with Felty’s syndrome, and23
the data must be independently confirmed. Another group
[86] compared α-G6PI antibody titres in serum and
synovial fluid and found increased concentrations of α-
G6PI antibodies in the synovial fluid of RA patients. Taken
together, the currently available data argue against a
pathogenic role for anti-G6PI immune responses in RA.
Are the immunological events that induce
arthritis in the K/B×N model relevant to RA?
Even if G6PI is not a relevant autoantigen to RA patho-
genesis, the question remains of whether the immunological
events that lead to the development of arthritis in the K/B×N
model are involved in human RA. Both experimental and
clinical data strongly support the possibility that
autoreactivity against systemically expressed autoantigens
may result in organ-specific autoimmune disease.
Systemic autoreactivity causes peripheral
neuritis in TCR transgenic mice
The K/B×N model is not the only transgenic model in
which organ-specific autoimmunity develops as a
consequence of systemic self-reactivity of T cells. Oono
and coworkers [87] produced transgenic mice that
express Eα52–68 covalently bound to the I-Ab molecule as
their only MHC peptide complex. These mice
spontaneously develop a CD4+ Th cell dependent
peripheral nervous system-specific autoimmune disease.
Neuritis in these TCR transgenic mice shares many of the
histopathological features found in experimental
autoimmune neuritis, including demyelination and axon
degeneration [87]. Serum from these transgenic mice did
not stain peripheral nerves and could not transfer the
disease to other animals [87].
Autoantibodies against systemically expressed
autoantigens are diagnostically important in
organ-specific autoimmune diseases
There are several clinical examples of autoantibodies
against systemically expressed autoantigens that are
highly sensitive and specific diagnostic markers for certain
organ-specific autoimmune diseases. These include the
anti-Jo-1 autoantibodies that bind to and inhibit activity of
histidyl-tRNA synthetase, and the autoantibodies that
recognize proteasomes that are found in different but
overlapping subsets of myositis patients [88–90]; the
antimitochondrial antibodies (AMA-2) that recognize the
E2 subunit of mitochondrial pyruvate dehydrogenise [91],
which are found in patients with primary biliary cirrhosis;
the autoantibodies against proteinase 3 (c-ANCAs) in
Wegener’s granulomatosis [92]; and, of course, the
rheumatoid factors that recognize IgG antibodies [8]. All
of these autoantibodies are directed against systemically
expressed autoantigens, yet they are highly specific and
sensitive markers for the respective diseases. However,
their pathogenic significance remains unknown, partly
because of the lack of suitable animal models.
Systemic autoreactivity causes severe
peripheral symmetrical polyarthritis in
genetically unaltered mice
To bridge the gap between the potentially very informative
yet rather artificial transgenic mouse models and the
situation in patients, we considered whether a systemic
immune response against G6PI could induce joint-specific
pathology in genetically unaltered mice. Of several inbred
strains tested, DBA/1 mice, the same inbred strain of mice
that is also susceptible to CIA, develop severe
symmetrical peripheral polyarthritis arthritis following one
single immunization with recombinant human or murine
G6PI in adjuvant [93] (Fig. 1). The incidence of arthritis
upon immunization is in excess of 90%, and the time
course is uniform and highly predictable. Clinical signs of
arthritis are first visible 9 days after immunization; the
arthritis then rapidly progresses, reaches its maximum at
about day 14 after immunization, and then slowly resolves.
The pattern of joints affected is similar to but not identical
to that observed in RA; wrists, metacarpal joints, proximal
and distal interphalangeal joints are affected at the front
limbs, and the tarsal, ankle and knee joints at the rear
limbs. Neither the spine, nor the hip, elbow, or shoulder
were affected in any of the animals analyzed [93].
Histologically, there are no further signs of inflammation
past day 21. Instead, reorganization and fibrosis become
visible. Importantly, there were no pathological findings in
any other organs apart from the joints. The sudden onset,
and high incidence and severity of arthritis distinguishes
this model from CIA. The spontaneous remission of G6PI-
induced arthritis in genetically unaltered DBA/1 mice is
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Figure 1
(a, b) Front and (c, d) hind limbs from DBA/1 mice that had been
immunized with glucose-6-phosphate isomerase (G6PI)
subcutaneously (panels b and d) or administered phosphate-buffered
saline subcutaneously (panels a and c) 14 days earlier. From [93], 
© 2004. The American Association of Immunologists, Inc. 
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one important clinical difference from the transgenic
K/B×N model. This allows for the study of the immuno-
logical mechanisms that modulate the autoimmune
response and induce remission of the disease.
Continuous requirement for Th cells in the
pathogenesis of G6PI-induced arthritis
Th cells are needed throughout the effector cells in G6PI-
induced arthritis in normal mice. Depletion of CD4+ cells
immediately after immunization prevents arthritis. More
importantly, depletion of CD4+ cell on days 11 and 14 (i.e.
when clinical symptoms are at their maximum) induces
rapid remission of arthritis both clinically and histologically
[93]. Thus, in G6PI-induced arthritis in normal mice, CD4+
cells are not only important in the induction but also
throughout the effector phase of the disease. This is in
contrast to the K/B×N model, in which Th cells are only
necessary to provide help to B cells that produce the
arthritogenic antibodies against G6PI. Once these
antibodies are produced, T cells are no longer necessary
for arthritis development in the K/B×N model, and transfer
of serum or antibodies from arthritic K/B×N mice [66,69]
can transfer arthritis to naïve recipients of almost any
mouse strain. Similarly, CIA can be transferred by
antibodies or serum [38–41] and it can be induced even
in the absence of CD4+ cells [47,48].
IgG antibodies are necessary but not sufficient
for G6PI-induced arthritis in normal mice
DBA/1 mice that lack the FcγR common γ chain and thus
cannot signal through the activating FcγRI and FcγRIII are
protected from G6PI-induced arthritis. In addition, mice
that lack the inhibitory FcγRIIB develop severe and
prolonged G6PI-induced arthritis (Fig. 2) [93]. Therefore,
IgG antibodies and FcγR+ effector cells are necessary for
the development of G6PI-induced arthritis. Nevertheless,
arthritis cannot be induced in naïve recipients by transfer
of serum or antibodies from arthritic DBA/1 mice [93]. It is
currently unclear why G6PI-induced arthritis cannot be
transferred with serum from arthritic animals; it is possible
that the antibodies present in the serum some 14 days
after immunization lack the necessary affinity for G6PI.
Thus, unlike the CIA and K/B×N models, both CD4+ T
cells and antibodies are necessary for the development of
G6PI-induced arthritis, and neither transfer of T cells nor
transfer of antibodies alone can induce arthritis in recipient
mice. TNF-α is indispensable for the development of
G6PI-induced arthritis in normal mice; treatment of mice
with the soluble p75 TNF receptor (etanercept)
completely prevents the development of arthritis [93].
Taken together, the above findings indicate that G6PI-
induced arthritis in genetically unaltered mice provides a
reliable and robust model in which the induction, effector
phase and modulation of organ-specific disease induced by
systemic autoimmunity can be dissected and therapeutically
targeted. Thus, G6PI-induced arthritis narrows the gap
between the TCR transgenic K/B×N model and the
situation in patients. Some of the major clinical and
immunological similarities and differences between CIA, the
K/B×N model and G6PI-induced arthritis are summarized in
Table 1. Several important questions remain unanswered.
Why the joint?
It is currently unclear why systemic autoreactivity against
the ubiquitously expressed glycolytic enzyme G6PI
specifically induces arthritis, with no other symptoms of
organ-specific or systemic autoimmune disease.
Interestingly, although GPI is ubiquitously expressed in the
body, the immune response against GPI appears to
initiate in the draining lymph nodes of peripheral joints in
K/B×N mice [94]. The reasons for this early localized
immune response are currently unclear but these findings
suggest that something unique to the joints initiates a
local immune response to a systemic autoantigen. This
contention is further supported by positron emission
tomography studies [95,96] that demonstrate rapid
localization of adoptively transferred antibodies against
G6PI to the peripheral joints of the recipient mice.
It is known that cationic antigens such as G6PI bind well
to cartilage [62,97]. However, systemically expressed
antigens such as G6PI are not only presented in the joint,
and not every cationic antigen induces arthritis upon
immunization. Immune complexes are a critical component
in the pathogenesis of K/B×N serum transfer arthritis
[96,98] and for G6PI-induced arthritis in normal mice
(unpublished observations). G6PI deposits, together with
IgG and C3, are detectable in the joints of arthritic mice in
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Figure 2
Arthritis scores of () DBA/1 wild-type, () DBA/1 FcγR common
γ-chain deficient, and () DBA/1 FcγRIIB deficient mice. Data are
presented as mean clinical scores ± standard error of the mean only
for those mice that developed arthritis. Arthritis incidence was 10/11 in
DBA/1 wild-type, 8/24 in DBA/1 FcγR common γ-chain deficient, and
16/16 in DBA/1 FcγRIIB deficient mice. From [93], © 2004. 
The American Association of Immunologists, Inc. 
Reprinted with permission.25
the K/B×N serum transfer model [98]. G6PI–IgG immune
complexes are also visible in the glomeruli of arthritic
K/B×N mice. In contrast to the joints, however, the
immune complexes in the kidney were not colocalized with
C3 [98]. It is has therefore been suggested that G6PI–
immunoglobulin immune complex trigger the complement
cascade exclusively in the joints. This would be explained
by the absence of membrane-bound C3 inhibitors from
chondrocytes [98]. The question remains as to why only a
particular pattern of joints is arthritic in the K/B×N model
and in G6PI-induced arthritis. Furthermore, immune
complex diseases do not necessarily induce erosive
arthritis. Systemic lupus erythematosus provides a
classical example; there, the immune complex induces
glomerulonephritis but not erosive arthritis.
Why G6PI?
Currently, there is no mechanistic explanation for the
association between autoantibodies against certain
systemically expressed antigens and particular auto-
immune diseases [8,88–92]. Similarly, it is not clear why
G6PI becomes the target of an arthritogenic autoimmune
response in K/B×N and DBA/1 mice. In addition to its
function as a glycolytic enzyme, G6PI can be secreted
and serves a variety of other physiological functions [99].
G6PI is identical to neuroleukin, a neurotrophic factor for
spinal and sensory neurones [100,101], which is
associated with terminal sprouting; autocrine motility
factor [102], which stimulates motility via a receptor-
mediated pathway [103]; and maturation factor, which
mediates the differentiation of human myeloid leukemic
HL-60 calls to terminal monocytic cells [104].
A receptor for G6PI, namely gp78, has been identified.
Gp78 is a transmembrane protein, a RING finger-
dependent ubiquitin protein ligase (E3) of the endo-
plasmatic reticulum [105,106]. It remains to be investiga-
ted whether one or more of these physiological functions of
G6PI contribute to its immunogenicity and arthritogenicity.
Conclusion
The search for arthritogenic autoantigens has long
focused on joint-specific antigens. The TCR transgenic
K/B×N model of arthritis and more recently G6PI-induced
arthritis in genetically unaltered mice have demonstrated
that a noncartilagenous systemically expressed self-
antigen can be the target of an arthritogenic immune
response. Although the two models exhibit clinical and
pathophysiological differences, a complex interplay
between cells and effector mechanisms of both the
adaptive and innate immune system is necessary in each
model. Whereas autoreactivity against G6PI does not
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Table 1
Clinical and pathological characteristics of different arthritis models in mice
Arthritis model
Characteristics Collagen-induced arthritis K/BxN arthritis G6PI-induced arthritis
Arthritogenic antigen Cartilage specific (CII) Systemic (G6PI) Systemic (G6PI)
Susceptible strain DBA/1 KRN TCR transgenic × NOD F1 mice DBA/1
Arthritis induction CII immunization and boost  Spontaneous G6PI immunization
Pathogenic cells and effector mechanisms
T cells ? Induction phase Induction and effector phases
Antibodies Necessary and sufficient Necessary and sufficient Necessary
FcγRI or FcγRIII necessary + + +
FcγR II  + + or – in different studies +
C5 + + +
Mast cells Uncertain + Unknown
Neutrophils + + Unknown
Macrophages Uncertain Unknown Unknown
TNF-α + (±) +
IL-1 + + Unknown
IL-6 + + Unknown
Spontaneous remission + – +
CII, type II collagen; G6PI, glucose-6-phosphate isomerase; TNF, tumor necrosis factor.26
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seem to play a role in RA, there are well known clinical
examples of autoantibodies that are directed against
autoantigens that are systemically expressed but
pathognomonic for organ-specific diseases, and the
possibility that arthritis may be induced by systemic
autoreactivity remains interesting and plausible. G6PI-
induced arthritis provides a model in which both the
induction and modulation of arthritis induced by
autoreactivity against noncartilagenous antigens can be
studied.
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